April 2024 in “Frontiers in pharmacology” This study compared JAK inhibitors for moderate-to-severe alopecia areata and found brepocitinib 30mg and deuruxolitinib 12mg to be most effective, though deuruxolitinib may cause more adverse events. Further research is needed for long-term efficacy and safety.
6 citations
,
February 2024 in “Journal of the American Academy of Dermatology” 
February 2024 in “Journal of the European Academy of Dermatology and Venereology” In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.
21 citations
,
February 2024 in “JAMA Dermatology” This study identified multiple factors affecting the severity of alopecia areata, suggesting they could inform a tool for measuring disease impact and guide treatment selection.
September 2023 in “British Journal of Dermatology” In this study, researchers identified subgroups of patients with severe alopecia areata treated with baricitinib who experienced early, gradual, or late hair regrowth, finding that response was influenced by baseline disease severity and duration of hair loss.
7 citations
,
August 2023 in “Journal of the American Academy of Dermatology” This source reports that the approval of baricitinib and ritlecitinib, which are JAK inhibitors, has marked a significant advancement in treating severe alopecia areata (AA), and suggests that additional treatments with new mechanisms may further improve patient outcomes in the future.
7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
12 citations
,
June 2023 in “JAMA network open” In this study of seven randomized clinical trials, JAK inhibitors were associated with improved hair regrowth outcomes in alopecia areata patients compared to placebo, with oral administration being more effective than external application, though longer trials are needed to confirm safety and effectiveness.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
148 citations
,
March 2022 in “The New England Journal of Medicine” In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.
16 citations
,
March 2022 in “Journal of Clinical Medicine” In this observational study, researchers found that mini-pulse oral corticosteroids effectively reduced hair loss in alopecia areata patients who did not respond to topical therapies, though early-onset patients and those with hypothyroidism were less likely to benefit.
23 citations
,
October 2020 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” This consensus report outlines Brazilian dermatologists' recommendations for treating alopecia areata, highlighting intralesional corticosteroids for localized cases and systemic therapy for extensive, active disease, along with monitoring side effects.
5 citations
,
July 2020 in “Journal of Cosmetic Dermatology” This study found that using a vibration anesthetic device during scalp mesotherapy significantly reduced pain in patients with androgenetic alopecia and alopecia areata compared to the non-vibration side.
3 citations
,
June 2020 in “Journal of Dermatological Treatment” In this study, researchers found that triamcinolone acetonide provided earlier visual improvement in alopecia areata treatment, but by 12 weeks, both triamcinolone acetonide and betamethasone 1.75 mg/ml showed similar effectiveness compared to lower-dose betamethasone and placebo.
19 citations
,
December 2019 in “Journal of the American Academy of Dermatology” This study suggests that intralesional triamcinolone acetonide at a concentration of 5 mg/mL may offer the best balance of effectiveness and safety for treating focal alopecia areata.
37 citations
,
December 2019 in “Giornale italiano di dermatologia e venereologia” This Italian guideline discusses the diagnosis and treatment of alopecia areata but reports no new clinical trial results; the authors highlight the need for well-designed studies.
23 citations
,
September 2019 in “Journal of The American Academy of Dermatology” In this retrospective analysis, combination therapy with tofacitinib and oral minoxidil led to significant scalp hair regrowth in patients with severe alopecia areata, with 67% achieving at least 75% regrowth, although the small sample size limits the findings.
44 citations
,
April 2019 in “Journal of the American Academy of Dermatology” This study observed that cyclosporine showed a trend toward improving alopecia areata symptoms compared to placebo, but the difference was not statistically significant.
20 citations
,
March 2019 in “Journal of The European Academy of Dermatology and Venereology” In this study, 5% minoxidil significantly improved outcomes for children and adults with patchy alopecia areata compared to placebo, with moderate quality evidence and no severe adverse events reported, though more research is needed to address remaining uncertainties.
4 citations
,
January 2019 in “Open Access Macedonian Journal of Medical Sciences” In this study, oral mini-pulse methylprednisolone therapy for alopecia areata was reported to be effective and safe over 6 months, with 82.2% of patients recovering well and no adverse events observed.
32 citations
,
November 2018 in “Anais Brasileiros de Dermatologia” This study highlighted the importance of aesthetic and common dermatological conditions such as acne and nonmelanoma skin cancer in Brazil, with varying patterns based on demographic and funding factors.
95 citations
,
November 2018 in “Australasian journal of dermatology” This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.
20 citations
,
August 2018 in “Clinics in Dermatology” This study highlights the significant psychological impact of alopecia areata, emphasizing the reciprocal relationship between the disorder and psychiatric issues, and underscores the importance of identifying patients needing additional psychological support, especially women, young individuals, and those with severe alopecia or previous psychiatric history.
11 citations
,
March 2018 in “Anais Brasileiros de Dermatologia” This article describes the DOAJ as a comprehensive index of diverse open access journals, emphasizing its commitment to freely providing quality content online, and reports no new findings.
15 citations
,
January 2018 in “Annals of Dermatology” Wigs significantly improve the well-being of people with severe hair loss.
28 citations
,
December 2017 in “Lasers in Medical Science” This review assessed evidence on laser therapies for alopecia areata, reporting that the 308-nm excimer laser showed hair regrowth in several studies, while more research is needed for other laser types.
182 citations
,
December 2017 in “Journal of the American Academy of Dermatology” This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.
39 citations
,
November 2017 in “Journal of The American Academy of Dermatology” This review presents standardized methods for assessing and tracking hair loss in alopecia areata but reports no clinical results, with the authors noting time limitations in clinical practice.
16 citations
,
May 2017 in “American Journal of Clinical Dermatology” This review discusses the clinical features, diagnosis, and treatment options for alopecia areata of the beard and reports no new clinical results.
21 citations
,
May 2017 in “Paediatric drugs” Individualized treatment plans are crucial for children with alopecia areata, with promising options like JAK inhibitors showing significant hair regrowth.
38 citations
,
March 2017 in “Expert Opinion on Investigational Drugs” This review examines the potential of bimatoprost for treating various types of eyelash and eyebrow hypotrichosis, discussing its pharmacological properties but providing no new clinical results.
11 citations
,
January 2017 in “Skin Appendage Disorders” This study associated ivory-colored areas observed through trichoscopy with steroid deposits in the dermis among patients with steroid-induced atrophy on the scalp.
16 citations
,
November 2016 in “Journal of Cosmetic and Laser Therapy” This review highlights that laser and light treatments could serve as safe and effective alternatives to current therapies for alopecia areata, with the excimer laser showing positive results, though further randomized controlled trials are necessary to establish optimal treatment protocols.
56 citations
,
October 2016 in “Journal of dermatological science” This review explores multidisciplinary advances in understanding alopecia areata, including epidemiology, pathogenesis, and innovative treatments, but reports no new research results.
17 citations
,
August 2016 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This study reported that 45.5% of patients with beard alopecia areata progressed to scalp alopecia areata within at least 12 months, with most cases occurring during the first year.
16 citations
,
March 2016 in “Clinical ophthalmology” In this study, bimatoprost 0.03% was effective and well-tolerated for improving eyelash hypotrichosis in healthy adolescents, but not for those with the condition due to chemotherapy or alopecia areata.
28 citations
,
January 2016 in “Dermatology” This study observed that methotrexate combined with low- to moderate-dose oral corticosteroids may effectively treat severe alopecia areata, though long-term maintenance is often necessary due to relapse after tapering.
14 citations
,
January 2016 in “Annals of dermatology/Annals of Dermatology” This study found that oral cyclosporine was more effective and had fewer side effects than betamethasone minipulse therapy for treating alopecia areata.
41 citations
,
November 2015 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This study found that diphenylcyclopropenone therapy resulted in over 50% hair regrowth in 71% of alopecia totalis patients, with a significant relapse association with thyroid disease, suggesting treatment could be viable but should continue for at least two years.
19 citations
,
October 2015 in “British Journal of Dermatology” This review reports very low quality evidence for the effectiveness and safety of treatments in extensive resistant alopecia areata and emphasizes the need for high-quality randomized controlled trials.
14 citations
,
September 2015 in “PubMed” This review discusses treatment strategies for alopecia areata and emphasizes the importance of primary care physicians recognizing and managing the condition, with referrals to dermatologists for more severe cases.
50 citations
,
July 2015 in “Journal of the American Academy of Dermatology” This study found that 2.5 mg/mL triamcinolone acetonide injections were as effective as higher doses for treating limited, patchy alopecia areata, while minimizing side effects like skin atrophy.
19 citations
,
June 2015 in “Seminars in Cutaneous Medicine and Surgery” This review discusses the clinical presentation, epidemiology, pathophysiology, and treatment options for alopecia areata and reports no new clinical findings.
44 citations
,
August 2014 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” This study found that methotrexate may be an effective and safe treatment option for severe alopecia areata, with better regrowth results when combined with corticosteroids.
701 citations
,
August 2014 in “Nature medicine” This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.
72 citations
,
July 2014 in “American journal of clinical dermatology” This review analyzed randomized controlled trials on alopecia areata treatment and found that while several treatments showed effectiveness, most studies had limitations affecting their interpretability.
9 citations
,
December 2012 in “The Journal of Dermatology” Wearing wigs or hairpieces improves self-esteem, adaptability, and competence in women with alopecia areata.
37 citations
,
September 2012 in “Archives of dermatology” Diphencyprone can help some children with alopecia areata regrow hair, but it often causes side effects.
49 citations
,
June 2012 in “Anais Brasileiros de Dermatologia” This study found that complaints of hair loss among adult female dermatology patients were associated with a higher prevalence of depression symptoms.
35 citations
,
May 2012 in “Expert Opinion on Pharmacotherapy” This review summarizes current and emerging treatments for common hair loss conditions, highlighting good evidence for androgenetic alopecia but noting the lack of long-term data for alopecia areata and cicatricial alopecias.
152 citations
,
April 2012 in “Recent Patents on Inflammation & Allergy Drug Discovery” This review describes minoxidil's hair regrowth mechanism and discusses dermatological applications, but reports no new clinical results, emphasizing the need for regular use and addressing allergic reactions.
20 citations
,
January 2012 in “International journal of trichology” In this study, among various treatments for localized alopecia areata, intralesional and topical steroids were found to be the most effective with no significant side effects.
51 citations
,
December 2011 in “The Journal of Dermatology” This review discusses updated treatment guidelines for alopecia areata in Japan, highlighting new options like corticosteroid pulse therapy, but reports no new clinical results.
48 citations
,
January 2011 in “International journal of trichology” This study found that intralesional triamcinolone acetonide was most effective for hair regrowth in localized alopecia areata, with betamethasone valerate foam also being beneficial, while tacrolimus ointment showed no significant effect.
244 citations
,
January 2010 in “Journal of the American Academy of Dermatology” This review discusses treatment options for alopecia areata and suggests tailored treatment plans, noting the challenges posed by spontaneous remission and limited high-quality clinical trials.
391 citations
,
January 2010 in “Journal of The American Academy of Dermatology” This article reviews the clinical presentation and histopathologic features of alopecia areata and proposes a hypothesis for its development, but it reports no new clinical results.
37 citations
,
January 2010 in “International Journal of Trichology” In this 1-year study of patients with alopecia areata universalis, researchers found that 0.03% topical bimatoprost led to an acceptable cosmetic response in 43.24% of participants.
97 citations
,
January 2006 in “Dermatology” This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.
141 citations
,
February 2005 in “Journal of the American Academy of Dermatology” In this study, oral prednisolone pulse therapy led to significant hair regrowth in some patients with extensive alopecia areata, whereas no improvement was seen in the placebo group.
397 citations
,
February 2004 in “British Journal of Dermatology” This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.
182 citations
,
October 2003 in “British Journal of Dermatology” These guidelines for alopecia areata management, prepared by the British Association of Dermatologists, provide evidence-based treatment recommendations and insights into the condition's epidemiology, diagnosis, and investigation.
17 citations
,
September 2003 in “Journal of Investigative Dermatology Symposium Proceedings” This study found that anthralin and mechlorethamine were the most effective therapies among those tested in AA-affected rodent models, providing a basis for further analysis of their mechanisms in Alopecia Areata.
146 citations
,
July 2003 in “Journal of the American Academy of Dermatology” In this study, clobetasol propionate 0.05% ointment was found to induce hair regrowth in 28.5% of patients with severe alopecia areata under occlusive conditions, though long-term benefit was limited to 17.8%.
59 citations
,
January 2002 in “Dermatology” This study suggests the existence of a new subtype of alopecia, called 'acute diffuse and total alopecia of the female scalp (ADTAFS)', characterized by acute, diffuse hair loss primarily in women and a rapid recovery.
117 citations
,
February 1996 in “International Journal of Dermatology” This study found that monthly oral prednisolone pulses of 300 mg were effective and safe for treating widespread alopecia areata, with 58.3% of patients achieving cosmetically acceptable hair growth.
34 citations
,
November 1987 in “Archives of Dermatology” This study found that oral minoxidil showed limited cosmetic effectiveness in treating severe alopecia areata, with only 18% of patients experiencing a noticeable response.
